Which factors predict success after discontinuation of inhaled budesonide therapy in children with asthma?

Journal of Asthma

Volumn 39, Issue 1, 2002, Pages 37-46

  Bahçeciler, Nerin Nadir ^a   Barlan, Işil B ^a   Nuhoǧlu, Yonca ^a   Başaran, Müjdat M ^a  

^a Vefa Bey Sok   (Turkey)

Author keywords

Asthma; Bronchial hyperreactivity; Discontinuation of therapy; Inhaled corticosteroids; Lung function; Urinary eosinophil protein X

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; EOSINOPHIL PROTEIN X; METHACHOLINE;

ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MALE; NEBULIZER; PREDICTION; PROPHYLAXIS; RECURRENT DISEASE; REMISSION; SCHOOL CHILD; SPIROMETRY; STEROID THERAPY; TREATMENT OUTCOME; URINALYSIS;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BUDESONIDE; CHILD; EOSINOPHIL-DERIVED NEUROTOXIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RIBONUCLEASES; SPIROMETRY; TIME FACTORS;

EID: 0036192255     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.1081/JAS-120000805     Document Type: Article

References (37)

1. Inflammation and airway function in asthma
2. Nonallergic airway responsiveness
3. Eosinophil derived cytokines in allergic inflammation and asthma
4. Eosinophils in allergy; role in disease, degranulation and cytokines
5. Asthma: Pathogenesis and treatment
6. Eosinophils and eosinophil-derived proteins in children with moderate asthma
7. Eosinophilic inflammation in asthma
8. Airway inflammation in mild intermittent and persistent asthma
9. Airway eosinophilic inflammation, epithelial damage, and bronchial hyperresponsiveness in patients with mild-moderate, stable asthma
10. Eosinophilic cationic protein levels in induced sputum correlate with the severity of bronchial asthma
11. Measuring airway inflammation in asthma: Eosinophils and eosinophilic cationic protein in induced sputtum compared with peripheral blood
12. Blood eosinophil number and activity in relation to lung function in patients with asthma and eosinophilia
13. Total blood eosinophils, serum eosinophilic cationic protein and eosinophil protein X in childhood asthma: Relation to disease status and therapy
14. Serum Eosinophil Peroxidase (EPO) levels in asthmatic patients
15. The use of serum Eosinophil Cationic Protein (ECP) in the management of steroid therapy in chronic asthma
16. Inflammatory markers of outcome
17. Urinary eosinophil protein X in relation to disease activity in childhood asthma
18. Urinary eosinophil protein X in children with atopic asthma: A useful marker of antiinflammatory treatment
19. Pulmonary function testing in childhood asthma
20. Current therapies for asthma
21. Efficacy and safety of inhaled corticosteroids: New developments
22. Standards for the diagnosis and care of patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma
23. Airway responsiveness. Standardised challenge testing with pharmacological, physical and sensitising stimuli in adults
24. Eosinophil cationic protein in peripheral blood of pediatric patients with allergic diseases
25. Effects of inhaled steroid treatment on serum Eosinophilic Cationic Protein (ECP) and low affinity receptor for IgE in childhood bronchial asthma
26. Airway function correlates with circulating eosinophil, but not mast cell, markers of inflammation in childhood asthma
27. Serum levels of eosinophil cationic protein and eosinophil protein X in pollen atopic patients with stable asthma and its relation with bronchial hyperresponsiveness
28. 20 and exacerbations
29. Do sputum eosinophils and ECP relate to the severity of asthma?
30. Comparison of basophil histamine release, eosinophil cationic protein and non-specific airway responsiveness between mite-sensitive asthmatic and non-asthmatic children and non-allergic controls
31. Clinical value of monitoring eosinophil activity in asthma
32. Evaluation of serum eosinophilic cationic protein as a marker of disease activity in chronic asthma
33. Twenty-four-hour time course of eosinophil granule proteins ECP and EPX during bronchial allergen challenges in serum of asthmatic children
34. Granulocyte proteins in serum in childhood asthma: Relation to spirometry and therapy
35. Asthma, bronchial hyperreactivity and mediator release in children with birch pollinosis ECP and EPX levels are not related to bronchial hyperreactivity
36. Eosinophil and mast cell parameters in children with stable moderate asthma
37. Evaluation of serum Eosinophil Cationic Protein (ECP) monitoring childhood asthma: ECP as a marker for indication and discontinuation of inhaled steroid therapy